Atlas Trials

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Clinical trial NCT03972306 · COMPLETED

Trial details

NCT number
NCT03972306
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Sclerosis (MS)
Start date
2019-08-12
Primary completion
2025-06-03
Enrollment
134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.